Compare Medpace Holdings Inc (MEDP) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Payoneer Global Inc — how do they compare? Medpace Holdings Inc trades at $617.27 (market cap $16.82B), while Payoneer Global Inc trades at $7.15 (market cap $2.43B). The key difference: Medpace Holdings Inc is far larger — about 6.9× Payoneer Global Inc's market cap, and Medpace Holdings Inc is more actively traded (223,093 versus 1,342,701). Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Payoneer Global Inc for 61 Days on average.
| MEDP | PAYO | |
|---|---|---|
Market Cap | $16.82B | $2.43B |
Volume | 223,093 | 1,342,701 |
Sector | Health | Technology |
52-Week High | $630.19 | $7.18 |
52-Week Low | $393.42 | $4.27 |
Typical Hold Time | 14 Days | 61 Days |
Enterprise Value | $16.44B | $2.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Payoneer Global (PAYO) trades at $7.16, showing minimal daily movement with a 0.14% gain. The stock maintains a bullish technical signal with strong moving average support, though oscillators remain neutral. Fundamentally, revenue grew to $821 million in 2025 with a 78% gross margin, but net income declined to $73 million. Recent news highlights the company's acquisition agreement with Nuvei and strategic expansion into India, while earnings show mixed quarterly performance with two misses and one beat in the last four quarters.
PAYO presents a mixed outlook with 60% analyst buy ratings supporting growth potential from international expansion and partnership renewals. However, declining profit margins, elevated P/E ratio of 51.18, and acquisition-related uncertainties pose significant risks. The stock's current technical strength contrasts with fundamental challenges, requiring careful monitoring of execution against growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
